Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia

MDM2 SNP 309 can lead to earlier onset or more advanced disease 6 and TP53 negatively regulates MDM2 expression, we assessed MDM2 SNP 309 alleles in isolation or in combination with TP53 Arg72Pro alleles against these clinical parameters; there was no evidence of any association (illustrated in Table Kaplan-Meier plots and log rank test statistics demonstrated no evidence for association of MDM2 SNP 309 or TP53 Arg72Pro allelic variants alone, or in combination, with overall survival (Figure